Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-12-04 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Second Commercial License Agreement with Genmab
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated '04 December 2024'. It contains standard regulatory boilerplate language, including references to 'RNS, the news service of the London Stock Exchange' and compliance with 'Article 7 of Regulation (EU) 596/2014 (MAR)'. The content itself is an announcement regarding a commercial license agreement exercise between Scancell Holdings Plc and Genmab. This type of immediate, brief corporate disclosure, especially when flagged with an RNS number and regulatory compliance statements, fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Therefore, it is best classified as a Regulatory Filing (RNS). The document length (6781 chars) is substantial enough that it is the primary announcement, not just a pointer to a report.
2024-12-04 English
Positive data from Phase 2 SCOPE trial with SCIB1
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 5202M' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and 'Article 7 of Regulation (EU) 596/2014 (MAR)'. The content is an announcement detailing positive clinical trial data (SCOPE trial for SCIB1) and includes contact information and company background. This format strongly indicates a regulatory news service announcement, which is the primary function of the RNS category. It is not a full Annual Report (10-K), a specific financial release (ER), or a management discussion (MDA), but rather a general, time-sensitive regulatory update.
2024-11-18 English
Group of companies' accounts made up to 2024-04-30
Regulatory Filings
2024-10-31 English
Result of Annual General Meeting
AGM Information Classification · 99% confidence The document is very short (3462 characters) and its primary content is an announcement stating that 'all resolutions proposed at the Annual General Meeting held today were duly passed.' This explicitly reports the outcome of a shareholder vote following an AGM. While it relates to an AGM, the specific action reported is the declaration of voting results. Therefore, the most precise classification is Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the AGM presentation itself (AGM-R), nor is it a general regulatory filing (RNS) since a more specific category exists.
2024-10-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 3797J' and contains the standard formatting for notifications distributed via RNS (Regulatory News Service), which is the news service of the London Stock Exchange, approved by the FCA. The content itself is a 'TR-1: Standard form for notification of major holdings'. This form reports changes in significant share ownership (crossing a threshold) by an entity (Calculus Capital Limited acting for Investec Wealth and Investment). This specific type of filing, reporting changes in major shareholdings, maps directly to the 'Major Shareholding Notification' definition. Code mapping: - Major Shareholding Notification maps to 'MRQ'. - Although it is distributed via RNS, the specific content type (TR-1 major holding notification) is more precise than the general 'RNS' fallback.
2024-10-24 English
Scancell Appoints Dr Phil L’Huillier as CEO
Board/Management Information Classification · 100% confidence The document is a formal announcement released via RNS (the news service of the London Stock Exchange), indicated by the 'RNS Number' and the closing footer referencing RNS and the FCA. The core content announces the appointment of a new Chief Executive Officer (Phil L'Huillier) and the transition of the current CEO (Lindy Durrant) to Chief Scientific Officer. This directly relates to changes in senior management and the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-10-22 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.